GRCL: רווח נקי למניה (EPS TTM) Gracell Biotechnologies Ltd
Gracell Biotechnologies (GRCL) aims for global leadership in CAR-T therapy for blood cancer through the expansion of clinical trials. The rolling earnings per share indicator demonstrates profit dynamics, where the value -1.01 captures the metric level. The innovative FasTCAR platform accelerates cell production, ensuring high margins and financial support from a pharmaceutical behemoth for the rapid market launch of drugs.
Gracell Bio - פילוחים אנליטיים ומדדי מפתח (GRCL)
Establishing a long-term position requires an assessment of the risk of capital freezing during market downturns. The strong pricing power of Gracell Biotechnologies (GRCL), driven by its rapid CAR-T cell production method, creates a foundation for revenue growth. The 12-month net income per share trend for Gracell Biotechnologies (GRCL) reflects the final financial result distributed across the total volume of issuance. This indicator compares the actual supply of securities with the real demand for a share of profits. The stability of this metric confirms the operational resilience of the business.
